CLDI Earnings Date: Nov 17, 2026 (Estimated) — Calidi Biotherapeutics, Inc.
AMEX · Healthcare · Biotechnology
Updated
When is CLDI's next earnings date?
Calidi Biotherapeutics, Inc. (CLDI) is expected to report Q3 2026 earnings on Tuesday, November 17, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company.
How did CLDI do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Calidi Biotherapeutics, Inc. posted EPS of -$2.94. Revenue was $0. The stock's 1-day post-earnings move was +3.2%.
How much does CLDI stock move after earnings?
CLDI beat EPS estimates in 3 of its last 5 reported quarters. Over the last 8 reports the stock moved an average of 3.4% (up or down) in the day after earnings.
About Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | — | -2.94 | — | $0 | — | +3.25% | -12.99% | -20.78% |
| 2026-05-14 | Q1 2026 | — | -0.43 | — | $0 | — | -2.24% | +1.05% | -14.61% |
| 2026-03-27 | Q4 2025 | -1.56 | -0.57 | +63.46% | $0 | ✅ Beat | -11.66% | -9.54% | -17.25% |
| 2025-11-13 | Q3 2025 | -1.68 | -2.21 | -31.55% | $0 | ❌ Miss | -1.32% | -9.21% | -12.50% |
| 2025-08-08 | Q2 2025 | -1.32 | -1.99 | -50.76% | $0 | ❌ Miss | +0.60% | +5.79% | -67.07% |
| 2025-03-31 | Q4 2024 | — | -0.27 | — | $0 | — | -1.61% | -12.38% | -14.78% |
| 2024-08-13 | Q2 2024 | -2.20 | -1.40 | +36.36% | $0 | ✅ Beat | -3.03% | -6.97% | -29.70% |
| 2024-05-14 | Q1 2024 | -2.70 | -2.00 | +25.93% | $0 | ✅ Beat | +3.45% | +4.52% | -2.57% |
Showing last 8 quarters.